Company Overview and News
ST. PAUL, Minn., Oct. 04, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE: FUL) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.155 per share of common stock. The dividend is payable on Nov.1, 2018 to shareholders of record at the close of business on Oct.18, 2018.
ful20180902_10q.htm Table of Contents
Third Quarter Diluted EPS $0.72 and Adjusted Diluted EPS $0.861; Fiscal Year 2018 Adjusted Diluted EPS Guidance Updated to $3.05 to $3.20; Unfavorable Foreign Exchange Rate Movement Impacted Adjusted EPS by approximately $0.10 in the Second Half of 2018
ST. PAUL, Minn., Sept. 14, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE: FUL) announced today that effective October 15, 2018, or as contracts allow, H.B. Fuller North America will implement price increases for all adhesives product categories and related products. Increases will be between 4 percent and 10 percent. These increases will affect products in the company’s durable assembly, hygiene, packaging, construction and paper converting segments.
2018-09-07 investorplace - 2
In a market near all-time highs, chemical stocks look like a potential source of value. Shares of top chemical companies still look reasonably cheap, with many priced at a mid-teen — or lower — multiples to earnings and free cash flow.
SEE ALB GRA LYB DWDP FUL LALWF DOW TSLA SQM TROX MMM
ST. PAUL, Minn., July 31, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE:FUL) announced today that, effective September 4, 2018, or as contracts allow, H.B. Fuller North America will implement price increases for all polymer and water-based adhesives product categories. Increases will be between 7 percent and 12 percent. These increases will affect products in the company’s packaging, durable assembly, construction and paper converting segments.
ST. PAUL, Minn., July 25, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller (NYSE:FUL) announced today that the company received a Strategic Supplier award from Faurecia Interior Systems, a global automotive parts manufacturer. This award recognizes H.B. Fuller, a leading global adhesives manufacturer, for outstanding quality, innovation, sustainability and economics in automotive interior adhesives.
ST. PAUL, Minn., July 18, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE:FUL) announced that it will host its 2018 Analyst and Investor Day live and by webcast on Thursday, July 19, from 9:00 a.m. to 12:00 p.m., EDT, in New York City. The conference will feature remarks by President and CEO James Owens and key members of H.B. Fuller’s management team. The Company will discuss its approach to enabling the world’s best innovations and review its long-term strategic plan.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
ECOR PLNT PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB AVRO HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV HCSG KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB FOXA CLW PM NTRSP AUTL DLPH SWKS GS SWK TRTX GM PII DIS NEE IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN XEL TGT BLK S PPG T SNE DPZ
ST. PAUL, Minn., July 12, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE:FUL) today announced that Daniel L. Florness was elected as an independent member to its board of directors, effective July 11, 2018. Florness’ position expands the board to 10 directors, nine of whom are independent.
ST. PAUL, Minn., July 12, 2018 (GLOBE NEWSWIRE) -- H.B. Fuller Company (NYSE:FUL) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.155 per share of common stock. The dividend is payable on August 9, 2018 to shareholders of record at the close of business on July 26, 2018.
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#,O2VED7!E+T=R;W5P+U,O5')A;G-P87)E;F-Y+T-3+T1E=FEC95)'0CX^+U1A8G,O M4R]3=')U8W1087)E;G1S(# ^/@T*96YD;V)J#0HT(# @;V)J#0H\/"]&:6QT M97(O1FQA=&5$96-O9&4O3&5N9W1H(#,P.38^
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to FUL / Fuller (H.B.) Co. on message board site Silicon Investor.
as of ET